Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework.
Weijia WangEdward LiKim CampbellAli McBrideSteve D'AmatoPublished in: JCO oncology practice (2021)
The implementation of biosimilar versus reference G-CSFs to OCM-participating practices results in a reduction of costs and facilitates achieving OCM metrics by improving patients' outcomes while expanding biosimilar G-CSFs access to patients at intermediate risk of chemotherapy-induced FN.
Keyphrases
- chemotherapy induced
- healthcare
- end stage renal disease
- palliative care
- primary care
- ejection fraction
- chronic kidney disease
- quality improvement
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- patient reported outcomes
- electronic health record
- pain management
- peripheral blood
- skeletal muscle
- health insurance
- patient reported
- affordable care act